پديدآورندگان :
Kanaani Leila Department of Toxicology, Faculty of Pharmacy, Islamic Azad University, Shahreza Branch, Shahreza, Iran , Akbarzadeh khiyavi Azim Department of Pilot Nanobiotechnology, Pasteur Institute of Iran, Tehran, Iran , Javadi Iraj Department of Toxicology, Faculty of Pharmacy, Islamic Azad University, Shahreza Branch, Shahreza, Iran , Mehrdiba Torkan mehrdiba_t@yahoo.com Department of Toxicology, Faculty of Pharmacy, Islamic Azad University, Ahar Branch, Ahar, Iran
چكيده فارسي :
Breast cancer is one of the most frequent cancer types within women population. Silibinin possesses a broad spectrum of biological applications such as anticancer activities; however, poorbioavailability reducesits efficacy at the tumour sites. This study aimd to prepare nanoniosoaml silibinin and evaluate its cytotoxicity against T-47D breast cancer cell line. Niosomes were prepared by revers phase evaporation method. For this purpose, certain amount of span 80, silibinin, poly sorbet-80,PEG-3350 and cholesterol were mixed together in chloroform. The solvent phase was evaporated by rotary evaporator and the remaining gellosephasewas hydrated in phosphate buffer saline. Mean size, size distribution and zeta potential of niosomes was measured by Zetasizer instrument. Releasing pattern of drug was evaluated by dialysis method and the cytotoxicity of nanoniosomes against T-47D cell line, was inspected by MTT assay. Release study showed nanoparticles have proper silibinin retention capability. So our findings suggest that silibinin niosomal nanocarriers could serve as a new drug formulation for breast cancer therapy.
